The global medical injection molding industry accelerates technological innovation, with Chinese companies capturing the market through localized services and precise manufacturing.

Since 2025, the global medical injection molding sector has shown a dual momentum of technological iteration and market expansion. According to the latest industry data, the global medical injection molding market reached $2.574 billion in 2025 and is expected to grow at a compound annual growth rate of 6.12% to reach $3.898 billion by 2032. Against this backdrop, both domestic and international companies are increasing their investment in precision equipment research and development, automation production line layout, and localization of service networks. Chinese enterprises are standing out in the global competition with customized solutions and efficient service responses.

From a technological breakthrough perspective,Miniaturized ManufacturingPlease provide the Chinese content that needs to be translated into American English.Efficient and Clean ProductionAt CHINAPLAS 2025, WITTMANN Group's MicroPower 15 micro-injection molding machine garnered significant attention for its ability to produce biodegradable medical surgical vascular clips weighing just 0.9mg. The machine achieves 8-hole simultaneous molding through a single female mold and double male mold design, maintaining an ultra-high precision of ±0.001mg in weight tolerance, reducing production cycles to 6.8 seconds. Paired with an automated robotic arm and optical inspection system, it achieves full-process unattended operation, improving efficiency by 60% over traditional equipment, with a 100% yield rate. It provides crucial support for the production of micro components in the fields of minimally invasive medical devices and diagnostic reagents. Suzhou Jestar (Jestada) relies on Arburg's all-electric injection molding machines to achieve high-precision medical component manufacturing in ISO 7-8 cleanrooms. Its 64-cavity hot runner mold has a shortest production cycle time of just 4.2 seconds, with a single machine's daily output exceeding 2.2 million pieces per product, maintaining an internal diameter tolerance of ±0.0025mm. To date, it has delivered over 1000 molds to the global medical industry, with more than 50% serving the medical niche markets of laboratory diagnostics and initial drug packaging.

Please provide the Chinese content you would like translated into American English.Automated Production LineThe company is focusing on building a full-process integrated solution for "Injection Molding - Assembly - Inspection - Packaging." This production line features a fully enclosed design, adaptable to various cleanroom grade requirements, and complies with GMP and ISO 13485 standards. It is also integrated with an MES system for real-time monitoring of production data, helping the company optimize process parameters and reduce the rate of defective products. Meanwhile, Shuangli Plastic Machinery showcases its equipment reliability in emergency medical production. Its high-speed injection molding machines, which make up the meltblown fabric mold production line, feature cleanroom-compatible design and short-cycle production capabilities. In the public health material guarantee, medical orders are prioritized through a "green channel" for production scheduling, and engineers are stationed on-site 24/7 to ensure stable operation of the equipment, providing support for the efficient supply of medical consumables.

Building Localized Service NetworkKey layout for corporate expansion into overseas markets. Seizing the potential of the Indonesian plastics market, which is expected to reach $14.58 billion by 2031, ICM has developed a dual strategy of "deepened service + local operations." In June of this year, a service center integrating display, testing, and spare parts warehousing was established in Semarang, Indonesia, significantly enhancing customer response speed in the Central Java region. Currently, the sales and service center in Surabaya is in the final stages of construction, with an expected opening in early 2026. Once operational, it will work in synergy with the Tanggerang, Cikarang, and Semarang outlets to cover the main industrial clusters on Java Island. At the Indonesia International Plastics and Rubber Industry Exhibition, ICM showcased the T260M hydraulic medical injection molding machine, optimized for 5ML jacket production with a 32-cavity design. The molding time is controlled at 15±1 seconds, and the risk of lubricant contamination is eliminated through the contactless rod (TBF) technology, increasing plasticization efficiency by over 20%. With solutions tailored to local needs, it has become an important choice for Indonesian medical manufacturing companies to upgrade their equipment.

Chinese companies are expanding their global market share thanks to a dual focus on technological innovation and localization of services. Jestar has established sales and service networks in Germany, Japan, Russia, Dubai, and other regions. The establishment of its Nuremberg branch in Germany in 2023 marks its transition from "China-made" to "global supply." Companies like Yizhimai and Guanshentai have built competitive advantages in emerging markets like Southeast Asia and the Middle East through customized equipment and efficient after-sales services. Industry analysis indicates that the medical injection molding industry will further develop towards "higher precision, more automation, and deeper localization." Companies with core technological reserves and comprehensive service systems will occupy a more important position in the global industrial chain, providing solid manufacturing support for the medical device industry.